CLINICAL_TRIALS
trial_result
· 2018-04-23
Clinical Trial Update: Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse [Phase 2]
Summary
Phase 2B/3 trial of tafenoquine for preventing relapse of vivax malaria has completed, with results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Malaria, Vivax | Phase 2 | Status: COMPLETED | Results posted: 2018-04-23